Development and Validation of a Clinical Risk Score Predicting the No-Reflow Phenomenon in Patients Treated with Primary Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction
机构:[1]Capital Med Univ, Chinese PLA Gen Hosp, Dept Cardiol, Beijing, Peoples R China;[2]Capital Med Univ, Beijing An Zhen Hosp, Dept Cardiol, Beijing, Peoples R China;临床科室心脏内科中心首都医科大学附属安贞医院[3]Capital Med Univ, Beijing Chao Yang Hosp, Dept Cardiol, Beijing, Peoples R China;内科系统(本部)心脏中心(本部)北京朝阳医院[4]Capital Med Univ, Beijing An Zhen Hosp, Emergency Ctr, Beijing, Peoples R China;临床科室急诊危重症中心首都医科大学附属安贞医院[5]Capital Med Univ, Beijing Tong Ren Hosp, Ctr Cardiovasc, Beijing, Peoples R China;首都医科大学附属同仁医院[6]Chinese Peoples Liberat Army Gen Hosp, Dept Cardiol, 28 Rd Fuxing, Beijing 100853, Peoples R China
Objective: The 'no-reflow' phenomenon after a primary percutaneous coronary intervention (pPCI) in patients with acute ST-segment elevation myocardial infarction (STEMI) is a strong predictor of both short- and long-term mortality. We therefore developed and prospectively validated a risk score system in order to identify STEMI patients at high risk in terms of no-reflow after primary PCI. Methods: The first part of our study used data from 1,615 STEMI patients who underwent primary PCI within 12 h from symptom onset. Using logistic regression, we derived a risk score to predict angiographic no-reflow using baseline clinical variables. From this score, we developed a simplified fast-track screen that can be used before reperfusion. In the second part of our study, we prospectively validated the score system using receiver-operating characteristic (ROC) curves with data from 692 STEMI patients. Results: The model included six clinical items: age, neutrophil count, admission plasma glucose, beta-blocker treatment, time-to-hospital admission and Killip classes. The risk score system demonstrated a good risk prediction with a c-statistic of 0.757 (95% CI 0.732-0.781) based on ROC analysis. Conclusion: A simple risk score system based on clinical variables is useful to predict the risk of developing no-reflow after pPCI in patients with STEMI. Copyright (C) 2013 S. Karger AG, Basel
基金:
Beijing Municipal Science and Technology Commission, ChinaBeijing Municipal Science & Technology Commission [Z09050700620909]
第一作者机构:[1]Capital Med Univ, Chinese PLA Gen Hosp, Dept Cardiol, Beijing, Peoples R China;
通讯作者:
通讯机构:[1]Capital Med Univ, Chinese PLA Gen Hosp, Dept Cardiol, Beijing, Peoples R China;[6]Chinese Peoples Liberat Army Gen Hosp, Dept Cardiol, 28 Rd Fuxing, Beijing 100853, Peoples R China
推荐引用方式(GB/T 7714):
Wang Jin-Wen,Chen Yun-Dai,Wang Chang-Hua,et al.Development and Validation of a Clinical Risk Score Predicting the No-Reflow Phenomenon in Patients Treated with Primary Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction[J].CARDIOLOGY.2013,124(3):153-160.doi:10.1159/000346386.
APA:
Wang, Jin-Wen,Chen, Yun-Dai,Wang, Chang-Hua,Yang, Xin-Chun,Zhu, Xiao-Ling&Zhou, Zi-Qiang.(2013).Development and Validation of a Clinical Risk Score Predicting the No-Reflow Phenomenon in Patients Treated with Primary Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction.CARDIOLOGY,124,(3)
MLA:
Wang, Jin-Wen,et al."Development and Validation of a Clinical Risk Score Predicting the No-Reflow Phenomenon in Patients Treated with Primary Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction".CARDIOLOGY 124..3(2013):153-160